The FDA Adopts the Abortion Industry Standards for the Mifeprex (RU-486) Abortion Regimen

The FDA Adopts the Abortion Industry Standards for the Mifeprex (RU-486) Abortion Regimen

On March 30, 2016, the U.S. Food and Drug Administration (FDA) announced changes to the labeling for the Mifeprex® (RU-486) abortion regimen. With these modifications, the FDA accepted wholesale the “off-label” regimen now being used by abortion providers like Planned Parenthood. These changes will greatly lower the already inadequate safety standards that had been put in place when the drug was first approved by the Clinton FDA in 2000. Below this brief description and initial analysis of the changes approved by the FDA, FRC summarizes the most recent adverse event data available, an FDA report from 2011, of the Mifeprex® abortion regimen.

Read the Full Publication